Jones Financial Companies Lllp Acquires 2,280 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Jones Financial Companies Lllp lifted its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 140.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,898 shares of the company’s stock after buying an additional 2,280 shares during the period. Jones Financial Companies Lllp’s holdings in Intellia Therapeutics were worth $45,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Generali Investments Towarzystwo Funduszy Inwestycyjnych lifted its stake in shares of Intellia Therapeutics by 77.1% in the fourth quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 62,000 shares of the company’s stock worth $723,000 after buying an additional 27,000 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of Intellia Therapeutics in the fourth quarter worth approximately $209,000. Whipplewood Advisors LLC bought a new position in shares of Intellia Therapeutics in the fourth quarter worth approximately $40,000. ARK Investment Management LLC lifted its stake in shares of Intellia Therapeutics by 2.3% in the fourth quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company’s stock worth $146,174,000 after buying an additional 280,946 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Intellia Therapeutics in the fourth quarter worth approximately $304,000. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Trading Down 4.1 %

Shares of NTLA stock opened at $9.19 on Wednesday. Intellia Therapeutics, Inc. has a 12 month low of $8.30 and a 12 month high of $28.54. The stock has a market cap of $951.32 million, a P/E ratio of -1.69 and a beta of 1.97. The company has a 50 day simple moving average of $10.23 and a two-hundred day simple moving average of $14.40.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on NTLA. Citigroup upped their target price on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. Chardan Capital decreased their price objective on shares of Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating for the company in a report on Friday, February 28th. The Goldman Sachs Group reissued a “sell” rating and set a $9.00 price objective on shares of Intellia Therapeutics in a report on Friday, February 28th. HC Wainwright started coverage on shares of Intellia Therapeutics in a report on Wednesday, March 5th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Truist Financial decreased their price objective on shares of Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $37.56.

Insider Transactions at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of the stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 29,000 shares of company stock valued at $352,551 over the last three months. Corporate insiders own 3.20% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.